BIO חוב כולל להון bio-rad.com

The asset value of Bio-Rad Laboratories (BIO) reflected in this chart demonstrates the financial health of a conservative laboratory equipment behemoth trusted by scientists worldwide. The business relies on the supply of high-tech systems and the recurring sale of ancillary consumables. The current figure is 0.20. Growth prospects are based on the resumption of investments in the biopharma sector and a stake in Sartorius, which strengthens its position in digital diagnostics.

The development of autonomous AI systems and the robotization of laboratory diagnostics require significant capital expenditures in high-tech manufacturing. An analysis of the total debt-to-equity ratio for Bio-Rad Laboratories (BIO) with a value of 0.20 allows for an assessment of the proportion of borrowed funds relative to equity, determining the financial stability of Bio-Rad Laboratories (BIO) and the risk of asset impairment as the cost of debt servicing rises.